RxDoctor Payments Data

Eric Landis, MD

Internal Medicine · Charlotte, NCNPI 1861414849

Payments from drug & device makers

$6,090in general payments, 2019–2025

Across 347 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$781
  • Amgen$612
  • AbbVie$585
  • Pfizer$389
  • AstraZeneca$369
  • GSK$353
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,060100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,090 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$202,389
Medicare patients
486
Services billed
4,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$105,824
OzempicSemaglutide44$66,643
FarxigaDapagliflozin Propanediol25$30,637
JanuviaSitagliptin Phosphate20$23,576
MounjaroTirzepatide23$23,409
TrulicityDulaglutide20$19,574
XareltoRivaroxaban19$19,054
Janumet XrSitagliptin Phos/Metformin Hcl20$18,237
SynthroidLevothyroxine Sodium82$9,115
Pitavastatin Calcium11$4,512
Atorvastatin Calcium530$4,174
Losartan Potassium417$3,817
Rosuvastatin Calcium392$3,792
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,700
Levothyroxine Sodium379$3,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$389$105,824112 claims
Novo NordiskOzempic$781$66,64344 claims
Lilly USA, LLCMounjaro, Trulicity$340$42,98343 claims
MerckJanuvia, Janumet Xr$167$41,81440 claims
AstraZenecaFarxiga, Symbicort$369$33,76838 claims
Johnson & JohnsonXarelto$219$19,05419 claims
AbbVieSynthroid$585$9,11582 claims
GSKShingrix$353$3,70017 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$109$3,524379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →